Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CNTX
stocks logo

CNTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2026Q1
--
--
-0.094
-57.14%
--
--
-0.110
+120%
Estimates Revision
The market is revising No Change the revenue expectations for Context Therapeutics Inc. (CNTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 25.55%.
EPS Estimates for FY2025
Revise Upward
up Image
+2.57%
In Past 3 Month
Stock Price
Go Up
up Image
+25.55%
In Past 3 Month
Wall Street analysts forecast CNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTX is 4.75 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast CNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTX is 4.75 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.030
sliders
Low
4.00
Averages
4.75
High
5.00
Current: 1.030
sliders
Low
4.00
Averages
4.75
High
5.00
H.C. Wainwright
Buy
maintain
$4 -> $5
2025-11-06
Reason
H.C. Wainwright
Price Target
$4 -> $5
2025-11-06
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Context Therapeutics to $5 from $4 and keeps a Buy rating on the shares following the Q3 report. The company noted a confirmed partial response in Cohort 3 for a patient with platinum resistant ovarian cancer, which is a "highly positive sign of activity," the analyst tells investors in a research note.
Guggenheim
Buy
initiated
$5
2025-09-17
Reason
Guggenheim
Price Target
$5
2025-09-17
initiated
Buy
Reason
Guggenheim initiated coverage of Context Therapeutics with a Buy rating and $5 price target.
Guggenheim
Buy
initiated
$5
2025-09-17
Reason
Guggenheim
Price Target
$5
2025-09-17
initiated
Buy
Reason
Guggenheim initiated coverage of Context Therapeutics with a Buy rating and $5 price target. The firm's investment thesis on the stock is centered on the company's differentiated approach to addressing "clinically validated but challenging" targets on solid tumors, which collectively represent a significant $30B U.S. total addressable market in aggregate across focus tumor type, the analyst tells investors in a research note. With shares trading at zero enterprise value, there is "asymmetric risk/reward" for Context Therapeutics, Guggenheim added.
H.C. Wainwright
Buy -> Buy
downgrade
$5 -> $4
2025-08-07
Reason
H.C. Wainwright
Price Target
$5 -> $4
2025-08-07
downgrade
Buy -> Buy
Reason
H.C. Wainwright lowered the firm's price target on Context Therapeutics to $4 from $5 and keeps a Buy rating on the shares following the Q2 report.
Piper Sandler
Overweight
downgrade
$4
2025-06-26
Reason
Piper Sandler
Price Target
$4
2025-06-26
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Context Therapeutics to $4 from $4.50 and keeps an Overweight rating on the shares after assuming coverage. Context Therapeutics is focused on the emerging T-cell engager modality, which has been validated by several recent clinical milestones and strategic acquisitions, the analyst tells investors in a research note.
William Blair
Matt Phipps
Buy
Initiates
n/a
2025-04-21
Reason
William Blair
Matt Phipps
Price Target
n/a
2025-04-21
Initiates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Context Therapeutics Inc (CNTX.O) is -2.36, compared to its 5-year average forward P/E of -2.75. For a more detailed relative valuation and DCF analysis to assess Context Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.75
Current PE
-2.36
Overvalued PE
-0.45
Undervalued PE
-5.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.17
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.27
Undervalued EV/EBITDA
-1.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
-0.55
Current PS
0.00
Overvalued PS
2.85
Undervalued PS
-3.96
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CNTX News & Events

Events Timeline

(ET)
2025-11-07
07:33:38
Context Therapeutics Showcases CT-95 and CT-202 Initiatives at SITC Conference
select
2025-11-05 (ET)
2025-11-05
17:57:27
Context Therapeutics Announces Q3 EPS of 10 Cents, Exceeding Consensus Estimate of 9 Cents
select
2025-08-06 (ET)
2025-08-06
17:52:14
Context Therapeutics reports Q2 EPS (9c), consensus (5c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-07Newsfilter
Context Therapeutics Showcases CT-95 and CT-202 Initiatives at the 2025 SITC Annual Meeting

  • Context Therapeutics Overview: Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumors, with two key programs, CT-95 and CT-202, presented at the SITC 40th Annual Meeting.

  • CT-95 Program Details: CT-95 is a bispecific T cell engager targeting mesothelin, currently in a Phase 1 trial with promising safety data, and initial results are expected in mid-2026.

  • CT-202 Program Insights: CT-202 targets Nectin-4 and shows strong preclinical activity, with plans to initiate a first-in-human trial by the second quarter of 2026 following necessary regulatory filings.

  • Forward-Looking Statements: The company’s press release includes forward-looking statements regarding future operations and expectations, which involve risks and uncertainties that could affect actual outcomes.

[object Object]
Preview
4.0
10-16Benzinga
D. Boral Capital Reiterates Buy Rating on Context Therapeutics with $9 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

[object Object]
Preview
5.0
10-04Newsfilter
Context Therapeutics Reveals Inducement Grant in Accordance with Nasdaq Listing Rule 5635(c)(4)

  • Stock Option Awards: Context Therapeutics Inc. granted non-qualified stock option awards for 30,000 shares to a new employee as an inducement for employment, with an exercise price of $0.97 per share.

  • Vesting Terms: The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the first anniversary and the remainder in monthly installments, contingent on continued service with the company.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Context Therapeutics Inc (CNTX) stock price today?

The current price of CNTX is 1.03 USD — it has decreased -5.5 % in the last trading day.

arrow icon

What is Context Therapeutics Inc (CNTX)'s business?

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.

arrow icon

What is the price predicton of CNTX Stock?

Wall Street analysts forecast CNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTX is 4.75 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Context Therapeutics Inc (CNTX)'s revenue for the last quarter?

Context Therapeutics Inc revenue for the last quarter amounts to -10.61M USD, decreased -43.26 % YoY.

arrow icon

What is Context Therapeutics Inc (CNTX)'s earnings per share (EPS) for the last quarter?

Context Therapeutics Inc. EPS for the last quarter amounts to -6578864.00 USD, increased 239.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Context Therapeutics Inc (CNTX)'s fundamentals?

The market is revising No Change the revenue expectations for Context Therapeutics Inc. (CNTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 25.55%.
arrow icon

How many employees does Context Therapeutics Inc (CNTX). have?

Context Therapeutics Inc (CNTX) has 12 emplpoyees as of December 05 2025.

arrow icon

What is Context Therapeutics Inc (CNTX) market cap?

Today CNTX has the market capitalization of 94.64M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free